Lamers CHJ, Sleijfer S, Willemsen RA, et al. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes[J]. J Biol Reg Homeos Ag, 2004, (18): 134-140.
[2]
Kawai K, Tani K, Yamashita N, et al. Advanced renal cell carcinoma treated with granulocyte-macrophage colony-stimulating factor gene therapy: a clinical course of the first Japanese experience[J]. Int J Urol, 2002, 9: 462-466.
Zhang Y, Luo CL, He BC, et al. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma[J]. Int J Oncol, 2010, 36(1): 133-140.
[5]
Calanis E, Burch PA, Richardson L, et al. Intratumoral administration of a 1, 2-dimyristyloxypropyl-3-dimthylhydro-xyethyl ammonium bromide/dioleoylphosphatidylethanolamine fomulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma[J]. Cancer, 2004, 101(11): 2557-2566.
[6]
Budryk M, Wilczynska U, Szary J, et al. Direct transfer of IL-12 gene into growing renca tumors[J]. Acta Biochim Pol, 2000, 47(2): 386-391.
[7]
Geiger JD. Vaccination of pediatric solid tumor patients specific T cells and mediate tumor regression[J]. Cancer Res, 2001, 61: 8513-8519.
Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, et al. HSV-tk gene therapy for human renal cell carcinoma in nude mice[J]. Cancer Gene Ther, 2001, 8(7): 529-536.
[11]
Pulkkanen KJ, Laukkanen JM, Fuxe J, et al. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice[J]. Cancer Gene Ther, 2002, 9(11): 908-916.
Lin PY, Fosmire SP, Park SH, et al. Attenuation of PTEN increases p2 1 stability and cytosolic, localization in kidney cancer cells: a potential mechanism of apoptosis resistance[J]. Mol Cancer, 2007, 6: 16.
Tavares TS, Nanus D, Yang XJ, et al. Gene microarray analysis of human renal cell carcinoma; the effects of HDAC inhibition and retinoid treatment[J]. Canc Bio Ther, 2008, 7(10): 1607-1618.
Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas[J]. Cancer Res, 2001, 61(3): 5215-5222.
[24]
Datta K, Sundberg C, Karumanchi SA, et al. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion[J]. Cancer Res, 2001, 61(5): 1768-1775.
[25]
Amato K, Robert J. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy[J]. Clin Genitourin Canc, 2007, 7(5): 422-426.
[26]
Yano T, Fujimoto E, Hagiwara H. Connexin 32 as an anti-invasive and anti-metastatic gene in renal cell carcinoma[J]. Biol Pharm Bull, 2006, 29(10): 1991-1994.
[27]
van Oosten RL, Earel JK, Griffith TS. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors[J]. Cancer Gene Ther, 2006, 13(5): 628-632.
[28]
Xu K, Ding Q, Fang Z, et al. Silencing of HIF-1α suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis[J]. Cancer Gene Ther, 2010, 17(3): 212-222.
[29]
Bui MH. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy[J]. Clin Cancer Res, 2002, 11(3): 2145-2151.
[30]
Lamers CJ, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous t-lymphocytes genetically retargeted against carbonic anhydrase Ⅸ: first clinical experience[J]. J Clin Oncol, 2006, 24(13): 20-22.
[31]
Lamers CJ, Langeveld SL, Groot-van Ruijven CM, et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo[J]. Cancer Immunol Immunother, 2007, 56: 1875-1883.
[32]
Nelson NJ. Faux chromosomes hit the street, hold real promise for gene therapy[J]. JNCI, 1997, 89(13): 908-910.
